2020 MELANOMA - POSTOW - Future Prospects for Immunotherapy Agents in Advanced Melanoma

Article and Video CATEGORIES

Cancer Journey

ABOUT

GRACE Videos and Articles

2020 MELANOMA - POSTOW - Future Prospects for Immunotherapy Agents in Advanced Melanoma

dbrock

Wed, 02/10/2021 - 17:25

2020 MELANOMA - Future Prospects for Immunotherapy Agents in Advanced Melanoma

Author

GRACE Videos and Articles

Download Transcript Here

GRACE is excited to bring you a new series on current updates in Melanoma Treatment.

Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University School of Medicine in Easton, PA joined GRACE to discuss current updates in treatment for Melanoma.

In this video, Dr. Postow discusses future prospects for immunotherapy agents in advanced melanoma.

A huge thank you to Merck for sponsoring this program.

Merck

To join the conversation, visit https://cancergrace.org/forum.

Video Language

English

Please feel free to offer comments and raise questions in our
discussion forums.

Join The conversation

Next Previous link

Previous Post Next Post

Article

The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.